Bausch Health Companies Inc. surprised investors with a significant earnings beat in Q2 2026, showcasing robust growth across key segments.
Bausch Health Companies Inc. (BHC.TO) reported its second-quarter earnings on July 29, 2026, revealing adjusted earnings of $1.26 per share, surpassing the consensus estimate of $1.01 by a remarkable 24.75%. This performance marks a continued trend of improvement for the company, as it has now beaten earnings estimates in three of the last four quarters.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.61B
52W high
$11.97
52W low
$6.10
1W change
+41.72%
Beta
0.38
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 22.7% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-22.7% Upside
Current Price
C$9.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
95.5%
Annualized
90-Day Vol
64.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$10.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.63 | C$6.92 – C$13.38 |
| 60 trading days | C$10.22 | C$6.41 – C$16.28 |
| 90 trading days | C$10.84 | C$6.13 – C$19.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 7 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-10-28 | — | 1.1700 | — |
| 2026-06-30 | 2026-07-29 | 1.2600 | 1.0100 | +24.8% |
| 2026-03-31 | 2026-04-29 | 0.7800 | 0.6900 | +13.0% |
| 2025-12-31 | 2026-02-18 | 1.1000 | 1.2100 | -9.1% |
| 2025-09-30 | 2025-10-29 | 1.1600 | 1.0600 | +9.4% |
| 2025-06-30 | 2025-07-30 | 0.9100 | 0.9400 | -3.2% |
Advertisement
Investor takeaway: The strong earnings report is a positive signal for investors, indicating that Bausch Health is effectively navigating its recovery and capitalizing on growth in its Salix and Solta Medical segments. However, caution is warranted as the stock has faced significant volatility this year.
Q2 2026 Earnings: EPS of $1.26 vs. $1.01 Expected (+24.75% Surprise)
Bausch Health's revenue for the quarter reached $2.85 billion, exceeding estimates by 7.62% and marking a year-over-year increase of 12.7%.
Bull case
Bausch Health's impressive earnings growth of 40% year-over-year, along with a raised revenue guidance for 2026, suggests a solid recovery trajectory. The strong performance in key segments like Salix and Solta Medical highlights the potential for continued growth.
Bear case
Despite the earnings beat, Bausch's stock has underperformed the market, losing about 35% year-to-date. Analysts remain cautious, with a bearish consensus rating reflecting concerns about long-term profitability and market dynamics.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
